Marta Dragosky

725 total citations
23 papers, 499 citations indexed

About

Marta Dragosky is a scholar working on Physiology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Marta Dragosky has authored 23 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Physiology, 12 papers in Molecular Biology and 8 papers in Organic Chemistry. Recurrent topics in Marta Dragosky's work include Lysosomal Storage Disorders Research (16 papers), Glycosylation and Glycoproteins Research (8 papers) and Carbohydrate Chemistry and Synthesis (8 papers). Marta Dragosky is often cited by papers focused on Lysosomal Storage Disorders Research (16 papers), Glycosylation and Glycoproteins Research (8 papers) and Carbohydrate Chemistry and Synthesis (8 papers). Marta Dragosky collaborates with scholars based in Argentina, United States and Israel. Marta Dragosky's co-authors include Elena Lukina, Nora Watman, Hanna Rosenbaum, Elsa Ávila Arreguin, Gregory M. Pastores, Ana Cristina Puga, Michel Peterschmitt, Daniel I. Rosenthal, Mici Phillips and Mathilde Kaper and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Hematology.

In The Last Decade

Marta Dragosky

22 papers receiving 476 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marta Dragosky Argentina 9 415 196 191 171 167 23 499
Nora Watman Argentina 12 570 1.4× 277 1.4× 256 1.3× 238 1.4× 212 1.3× 30 719
C. E. Hatton United Kingdom 9 337 0.8× 109 0.6× 71 0.4× 61 0.4× 157 0.9× 11 471
Deborah Elstein Israel 12 412 1.0× 159 0.8× 140 0.7× 203 1.2× 148 0.9× 31 477
Derlis Gonzalez United States 8 195 0.5× 77 0.4× 88 0.5× 91 0.5× 74 0.4× 16 256
Juan M. Mucci Argentina 12 286 0.7× 78 0.4× 44 0.2× 92 0.5× 127 0.8× 18 348
Gabriela Pasqualim Brazil 13 258 0.6× 114 0.6× 54 0.3× 64 0.4× 155 0.9× 31 397
Carmela Zizzo Italy 14 384 0.9× 140 0.7× 122 0.6× 117 0.7× 137 0.8× 34 490
H.C. Janse Netherlands 11 268 0.6× 96 0.5× 63 0.3× 84 0.5× 127 0.8× 17 404
Guillermo Drelichman Argentina 9 187 0.5× 79 0.4× 81 0.4× 73 0.4× 62 0.4× 23 412
Yoshimi Ogawa Japan 6 254 0.6× 147 0.8× 97 0.5× 117 0.7× 124 0.7× 7 401

Countries citing papers authored by Marta Dragosky

Since Specialization
Citations

This map shows the geographic impact of Marta Dragosky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Dragosky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Dragosky more than expected).

Fields of papers citing papers by Marta Dragosky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Dragosky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Dragosky. The network helps show where Marta Dragosky may publish in the future.

Co-authorship network of co-authors of Marta Dragosky

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Dragosky. A scholar is included among the top collaborators of Marta Dragosky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Dragosky. Marta Dragosky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosenbloom, Barry E., Maria Domenica Cappellini, Neal J. Weinreb, et al.. (2022). Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry. American Journal of Hematology. 97(10). 1337–1347. 17 indexed citations
2.
Deza, Ernesto Gil, et al.. (2021). COVID-19 and medical education: Rethinking student assessment—The Virtual Observational Standard Clinical Examination.. Journal of Clinical Oncology. 39(15_suppl). 11005–11005. 1 indexed citations
3.
Drelichman, Guillermo, Gilberto Castañeda‐Hernández, Muhlis Cem Ar, et al.. (2019). The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease. American Journal of Hematology. 95(3). 233–237. 9 indexed citations
4.
Lukina, Elena, Nora Watman, Marta Dragosky, et al.. (2018). Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial. American Journal of Hematology. 94(1). 29–38. 49 indexed citations
5.
Camelo, José Simon, Marta Dragosky, & Guillermo Drelichman. (2016). DOENÇA DE GAUCHER TIPO 1 NO ESQUELETO: REVISÃO DA AMÉRICA LATINA. Coluna/Columna. 15(4). 317–324. 2 indexed citations
6.
Lukina, Elena, Nora Watman, Marta Dragosky, et al.. (2014). Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Molecules and Diseases. 53(4). 274–276. 61 indexed citations
7.
Kamath, Ravi S., Elena Lukina, Nora Watman, et al.. (2014). Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiology. 43(10). 1353–1360. 47 indexed citations
8.
Peterschmitt, Michel, Elena Lukina, Nora Watman, et al.. (2012). Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment. Blood. 120(21). 1038–1038. 2 indexed citations
9.
Peterschmitt, Michel, Elena Lukina, Nora Watman, et al.. (2012). Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1 (GD1): Updated Phase 2 Results. Molecular Genetics and Metabolism. 105(2). S52–S52. 1 indexed citations
10.
Peterschmitt, Michel, Elena Lukina, Nora Watman, et al.. (2011). Eliglustat, An Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 3 Years. Blood. 118(21). 1104–1104. 2 indexed citations
11.
Peterschmitt, Michel, Ravi S. Kamath, Elena Lukina, et al.. (2011). Improvements in Skeletal Manifestations in Gaucher Disease Type 1 Patients After 3 Years of Treatment with Oral Eliglustat During a Phase 2 Trial,. Blood. 118(21). 3216–3216. 1 indexed citations
12.
Puga, Ana Cristina, Elena Lukina, Nora Watman, et al.. (2011). Eliglustat, an investigational oral therapy for gaucher disease type 1 (GD1): Phase 2 results and assessment of patient responses and achievement of established therapeutic goals after 2 years of treatment. Molecular Genetics and Metabolism. 102(2). S37–S37. 2 indexed citations
13.
Lukina, Elena, Nora Watman, Elsa Ávila Arreguin, et al.. (2010). A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 116(6). 893–899. 120 indexed citations
14.
15.
Lukina, Elena, Nora Watman, Marta Dragosky, et al.. (2010). Eliglustat Tartrate, a Novel Investigational Oral Substrate Reduction Therapy for Gaucher Disease Type 1: Updated Phase 2 Results.. Blood. 116(21). 3791–3791. 1 indexed citations
16.
Lukina, Elena, Nora Watman, Elsa Ávila Arreguin, et al.. (2009). Genz-112638 for Gaucher Disease Type 1: Phase 2 Clinical Trial Results After 18 Months of Treatment.. Blood. 114(22). 1349–1349. 3 indexed citations
17.
Lukina, Elena, Nora Watman, Elsa Ávila Arreguin, et al.. (2009). 102. Genz-112638, an investigational oral treatment for Gaucher disease type 1: Preliminary Phase 2 clinical trial results. Molecular Genetics and Metabolism. 96(2). S34–S34.
18.
Dragosky, Marta, et al.. (2000). [Single extramedullary plasmacytoma of the nose].. PubMed. 51(4). 348–52. 5 indexed citations
19.
Fainboim, Leonardo, et al.. (1985). Immunological phenotype of leukaemias and lymphomas in Argentina. Leukemia Research. 9(6). 813–816. 2 indexed citations
20.
Dragosky, Marta, et al.. (1982). [Myelopoietic effect of medroxyprogesterone acetate at high parenteral doses in the cancer patient].. PubMed. 27(5). 883–90. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nora Watman Breakdown of academic impact, for papers by C. E. Hatton Breakdown of academic impact, for papers by Deborah Elstein Breakdown of academic impact, for papers by Derlis Gonzalez Breakdown of academic impact, for papers by Juan M. Mucci Breakdown of academic impact, for papers by Gabriela Pasqualim Breakdown of academic impact, for papers by Carmela Zizzo Breakdown of academic impact, for papers by H.C. Janse Breakdown of academic impact, for papers by Guillermo Drelichman Breakdown of academic impact, for papers by Yoshimi Ogawa
Rankless by CCL
2026